In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we explore how CDMOs are reshaping supply‑chain strategy for a new generation of complex modalities.

Original title: “The supply chain fault lines of modern pharma”

Last month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines’ layoffs will affect the most employees.

Original title: “August biopharma layoffs impact just over 500, down 90% year over year”

Applying artificial intelligence and automation tactics has played a large role in talent strategy conversations in the past few years. While many organizations initially focused on experimenting with tools and driving adoption to create efficiencies, leading employers are now asking deeper questions.

Original title: “From process to intelligence: How AI is reshaping people strategy in life sciences”

Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

Original title: “11 companies hiring in California now”

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

Original title: “Kura spins diabetes work into a Lilly-backed biotech startup”

After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.

Original title: “FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders”

Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.

Original title: “Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets”

The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion of its portfolio.

Original title: “Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision”

The decision to promote Michael Davis and Karim Mikhail from acting to permanent division heads comes as the FDA awaits the potential confirmation of Heidi Overton, President Donald Trump’s nominee for commissioner.

Original title: “Acting CBER, CDER heads become permanent as FDA works to restore stability”

Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, according to BMO Capital Markets.

Original title: “BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’”

Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from China’s Harbour BioMed.

Original title: “Solstice rises with $225M to develop next-gen CTLA-4 drug from China”

Kura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes.

Original title: “Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet”

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.

Original title: “A new immuno-oncology play raises $225M for a next-generation drug”

As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.

Original title: “Beyond China: Five other overseas destinations for biopharma dollars”

Multi-agent AI reasoning at the point of care, with complete data sovereignty built in.

Original title: “Six AI agents, one deskside system: A new model for clinical decision support”

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

Original title: “Moonwalk reloads with $70M and new RNAi prospects for obesity”